Stefan Aebi

Senior Consultant, Med Oncology, Lucerne Cancer Center. Emeritus Prof University of Berne. Tweets my own.

[ETOP IBCSG Partners Foundation @etop_ibcsg]

New publication: Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials
https://t.co/7LAOi9HGPA

[Krebsforschung Schweiz @Krebs_Forschung]

Heute ist #Weltkrebsforschungstag
Die #Krebsforschung und die #Krebsliga Schweiz erhalten jährlich rund 200 Forschungsprojekte. Bei der Prüfung dieser Gesuche kommt der unabhängigen Wisschenschaftlichen Kommission eine zentrale Rolle zu. 

➡ https://t.co/W4pFul7u9r

#WCRD

[ESMO - Eur. Oncology @myESMO]

📣 Registration for #ESMOAcademy24 is now open. Get your update on the key topics in #medicaloncology. Register now: 👉 https://t.co/1EY5JLzYpb

@caliraf @dplanchard @peters_solange @BanerjeeSusana @amanda_psyrri @curijoey @LizzySmyth1 @MacarullaTeresa

[Luzerner Kantonsspital @KantonsspitalLU]

Die Europäische Gesellschaft für medizinische Onkologie (ESMO) anerkennt das Tumorzentrum des LUKS als Zentrum mit integrierter Onkologie und Palliativbetreuung.

Mehr Informationen finden Sie hier:
https://t.co/CEiRrZctGo

[Icro Meattini @Icro_Meattini]

Ready for 2 days of exciting discussion @myESMO preceptorship on #breastcancer in Lugano

Amazing faculty and super participants

@OncoAlert #OncoAlert #radonc #medonc #surgonc

[Universität Luzern @UniLuzern]

Der Schweizerische Akkreditierungsrat hat dem Joint Medical Master die Akkreditierung ohne Auflagen erteilt. Das #Masterstudium in #Humanmedizin wird von der #UniLuzern in Zusammenarbeit mit der @UZH_ch angeboten.
https://t.co/hH1QmEHoaT

[Elisabetta Munzone @elisabettasabet]

📢 Finally out ‼️Oral VEX (Vinorelbine, Cyclophosphamide, and Capecitabine) vs Paclitaxel for Metastatic ER+/ERBB2− Breast Cancer improves TTF & PFS
https://t.co/zgW7hN4I7s…
@etop_ibcsg @IEOufficiale
#metronomicVEX; #breastcancer #noalopecia #oralchemotherapy

[ESMO - Eur. Oncology @myESMO]

#ESMOAcademy23: Gain expertise in methodology & interpretation of clinical trials, standard of care & future perspectives in main tumour types, pharmacokinetics & drug interactions at this comprehensive update on key topics in #medicaloncology.

Register 👉https://t.co/eULRao6qJb

[Stefan Aebi @AebiSP]

Im Namen der Medizinischen Onkologie des Luzerner Kantonsspitals gehen unsere Glückwünsche zur verdienten Anerkennung an Prof. Ruedi Joss

https://t.co/JvC4JCWp1l

[Elisabetta Munzone @elisabettasabet]

📢 Finally out #POSITIVE TRIAL ‼️wonderful news for #premenopausal #breastcancer patients who interrupt #EndocrineTherapy to Attempt #Pregnancy @etop_ibcsg ⁦@IEOufficiale⁩ ⁦@NEJM⁩ https://t.co/Q5DHbWxyh2

[Richard Schilsky @rschilsky]

Thanks Winette and @EORTC for organizing a terrific workshop on pragmatic trials!

[ETOP IBCSG Partners Foundation @etop_ibcsg]

Just out in Annals of Oncology - Results of the IBCSG 24-02 / BIG 2-02 (SOFT) trial: "Genomic characterisation of hormone receptor-positive breast cancer arising in very young women". https://t.co/SrC3G7sYZW
@BIGagainstBC

[Elisabetta Munzone @elisabettasabet]

@DrSGraff POLAR trial will probably answer the question: does 3yrs palbo+ET vs ET alone prolong iDFS in HR+/HER2- resected ILRR? @etop_ibcsg @BIGagainstBC @IEOufficiale

[Elisabetta Munzone @elisabettasabet]

There’s a trial on #mondaymorning to answer the question raised by #SGBCC2023 panelists: ET+CDK4/6i vs ET for HR+HER2- #ILRR
#POLAR trial @etop_ibcsg @BIGagainstBC @IEOufficiale @AebiSP

[Stefan Aebi @AebiSP]

Well deserved - congratulations Professor Viale

[SGBCC @SG_BCC]

We are happy to announce that the #SGBCC2023 Award Winner is Giuseppe Viale, who will be honoured with his #award during the Opening Ceremony of the #Congress. Prof. Viale has devoted decades of his career to #breastcancer research as a leading scientist globally. #SGBCCAward

[ETOP IBCSG Partners Foundation @etop_ibcsg]

The long-awaited initial results of the IBCSG 48-14/BIG 8-13 POSITIVE Trial will be presented at SABCS 2022 this Friday, Dec 9. Join online or in Hall 3 at 11:00am CT.
@BIGagainstBC, @ALLIANCE_org, @_SOLTI, @GEICAM, @SAKK_ch, @cancertrials_ie, @ABCSGVienna

[SAMO @SamoWorkshop]

Please register for our „Highlights of the Year“ onsite session in Berne on November 24 chaired by Rolf Stahel and @peters_solange ! Link: https://t.co/kIQXOQVU6J

[Stefan Aebi @AebiSP]

Excellent presentation of a contemporary trial of metronomic therapy for patients with advanced breast cancer #ESMO22

[Elisabetta Munzone @elisabettasabet]

Proud to share the results of the METEORA-II trial. Metronomic oral VEX vs paclitaxel significantly improved TTF (HR 0.61), and mPFS (11.1 vs 6.9 mo HR0.67) in pts with ER+/HER2- metastatic #breastcancer.
#ESMO22 @myESMO @etop_ibcsg @IEOufficiale

[Stefan Aebi @AebiSP]

Great achievement - congratulations to our @SamoWorkshop board member.

[Fred R. Hirsch @fred_hirsch]

Proud to see my named award going to a very distinguished investigator at the World Lung Cancer Conference

[Tumori Journal @TumoriJ]

#WORLDLUNGCANCERDAY2022 #WorldLungCancerDay 🫁

Dr Paola Perego and Dr Mattia Boeri discuss the usefulness of #liquidbiopsy🩸for the management of #lungcancer and the next frontiers of its clinical application👇
🔗https://t.co/W7v4iZRiIx

@IstTumori #biomarker #screening #lcsm